Page 11234..1020..»

Inspired by cancer research: ‘It’s not the death sentence it once was’ – Bega District News

Posted: May 29, 2017 at 4:54 pm

Kylie ONeill knows only too well the unforgiving and indiscriminate nature of cancer.

SUPPORTIVE: Kylie O’Neill of Angledale with her grandaughter Amaya of Tura Beach at Brogo’s Biggest Morning Tea on Friday. Picture: Alasdair McDonald

She has lost her best friend, her sister-in-law and her 22-year-old nephew to a disease that kills tens of thousands of Australians each year.

Angledales Kylie ONeill, like many other Australians, knows only too well the unforgiving and indiscriminate nature of cancer.

With my sister-in-law, if she had cancer now she would have survived due to the advancements in research, so raising money is very important, Ms ONeill said during BrogosBiggest Morning Tea Cancer Council fundraiser on Friday.

If we didnt have Pap smears I would be dead, so Im very thankful. – Kylie O’Neill

She left children behind, and my brother has never really recovered because he became the main caregiver.

It has fractured their lives.

The Angledale resident said the disease is not the death sentence it once was, andregular Pap smears have helped saved her life.

If we didnt have Pap smears I would be dead, so Im very thankful, she said.

We know people who have survived, because researchers are making breakthroughs every day.

So, the more money we can put into research and innovation, the more we can understand about it.

Maree and Amelia Walsh of Wolumla with Bea Bagguley of Bega and Charlotte Rowe of Cooma at Brogo’s Biggest Morning Tea on Friday. Picture: Alasdair McDonald

According to the Australian Cancer Research Foundation,123,000 new cases of cancer are diagnosed in Australia every year, and as our population ages, the disease is becoming more prevalent. Over the last three decades, the survival rate for many types of cancer has increased by more than 20 per cent due to treatment improvements and new interventions.

Ms ONeill is inspired by the breakthroughs brought around by research, and recommended all Australians receive annual checks, and visit their doctor regularly.

She said she is optimistic future generations will not suffer what those close to her have in recent years.

Seeing your doctor regularly at the very least means you can develop a nice relationship together, Ms ONeill said.

The Brogo event raised over $2000 for the Cancer Council, with organiser Lenna Pearce estimating more than 100 people passed through the doors in a locality of just over 500 people.

Theres a lot of new faces here Ive never seen before, Ms Pearce said.

Continued here:
Inspired by cancer research: ‘It’s not the death sentence it once was’ – Bega District News

Posted in Cancer Research | Comments Off on Inspired by cancer research: ‘It’s not the death sentence it once was’ – Bega District News

Raising age limit for routine genetic testing in colorectal cancer could identify more cases of Lynch syndrome –

Posted: at 4:53 pm

May 29, 2017

Raising the age limit for routine genetic testing in colorectal cancer could identify more cases of families affected by Lynch syndrome, a condition that accounts for around 5% of all colon cancers, according to new research to be presented at the annual conference of the European Society of Human Genetics today (Monday). Professor Nicoline Hoogerbrugge, head of the Radboud university medical center expert center on hereditary cancers, Nijmegen, The Netherlands, will tell the conference that there is an urgent need to find families carrying a mutation for Lynch syndrome in order to decrease mortality from the disease.

“We know that, at present, only between 20% and 30% of people with Lynch syndrome have been identified. Most countries rely on detection through family history and early age at diagnosis, and this leads to significant underdiagnosis. We have shown that, by raising the age limit for testing we are able to detect new affected families who would not have been identified previously,” she says.

The researchers studied results of mismatch repair (MMR) testing in patients up to 70 years of age with colorectal cancer from 14 pathology laboratories. Previously, in The Netherlands, such testing was carried routinely in patients who were aged up to 50. Of 87 patients whose results suggested that they are at high risk of Lynch syndrome, 35 were referred for genetic counseling.

After further testing, Lynch syndrome mutations were definitely identified in 13 of 32 patients with complete genetic testing, and 11 of these patients came from families in which the disease had previously not been detected. Eight of them were aged between 50 and 70 and did not comply with previous referral criteria for genetic testing based on age and family history.

“If we had not studied these older patients, their family predisposition to Lynch syndrome would not have been detected until it was too late,” says Prof Hoogerbrugge. “In every affected family, we can find an average of three people with Lynch. This is clearly a massive advance in the identification of people at risk.”

By implementing appropriate prevention measures, deaths from Lynch syndrome in affected families can be reduced by more than 60% over 15 years, the researchers say. The disease, otherwise known as hereditary nonpolyposis colorectal cancer (HNPCC), also leads to an increased risk of cancers of the stomach, upper urinary tract, brain, skin and prostate, with women carriers at an additional of endometrial and ovarian cancers.

The study covered 20% of the Dutch population. “Part of our results surprised us; we had not expected to find so many mutations in Lynch syndrome associated genes with a relatively high risk of developing tumors in patients without a family history of the disease. This has only strengthened our desire to see an increase in the age limit for MMR testing applied across The Netherlands, and indeed across Europe, so that every new colorectal cancer patient aged below 70 can benefit from it,” says Prof Hoogerbrugge.

“The age limit in the UK has recently been increased; although it is too early to be able to see signs of value there, we have been able to provide clear evidence of its advantages in The Netherlands, both for patients and for health services,” she concludes.

Chair of the ESHG conference, Professor Joris Veltman, Director of the Institute of Genetic Medicine at Newcastle University, Newcastle, United Kingdom, said: “It is very important to recognize whether a person suffers from sporadic or familiar cancer, as this identifies family members at risk who can take preventative measures. For this, genetic tests need to be done in cancer patients. This study shows that we should extend these genetic tests to older colorectal cancer patients of whom a significant number suffer from familiar cancer.”

See the original post:
Raising age limit for routine genetic testing in colorectal cancer could identify more cases of Lynch syndrome –

Posted in Cancer Genetics | Comments Off on Raising age limit for routine genetic testing in colorectal cancer could identify more cases of Lynch syndrome –

Letter, 5/28: Center boosts ovarian cancer hope – Lincoln Journal Star

Posted: at 4:53 pm

Joe Biden’s applauding the Buffett Cancer Center for cancer research to find cures for this disease gives hope to cancer patients. In curing and managing cancer, oncologists and OB-GYNs say early detection is important.

Ovarian cancer affects approximately 200,000 women in the United States, which represents 4 percent of cancer patients. They call this cancer “the one that whispers,” as it is difficult to detect. In many cases, it’s discovered during surgery.

For women being treated with chemotherapy, oncologists run a blood test called CA125, which measures the amount of the protein (Cancer Antigen 125) in your blood. This test should be considered to be used for early signs of ovarian cancer but is rarely used by OB-GYNs.

Based on current data, normal CA125 levels would be 0-35; higher levels may indicate ovarian cancer. Women older than 70 and a history of family cancer appear to be at the highest risk.

Many OB-GYNs do not routinely run this test. Insurance coverage is questionable. However, most men get a PSA blood test during their annual physical to detect prostate cancer.

Perhaps our approach for early detection of ovarian cancer will change with more emphasis on this disease through the Buffett Cancer Center.

Excerpt from:
Letter, 5/28: Center boosts ovarian cancer hope – Lincoln Journal Star

Posted in Ovarian Cancer | Comments Off on Letter, 5/28: Center boosts ovarian cancer hope – Lincoln Journal Star

A drink a day tied to higher breast cancer risk, report says …

Posted: at 4:52 pm

Sipping an average of 10 grams of alcohol a day — equivalent to a small glass of wine, an 8-ounce beer or 1 ounce of hard liquor — is associated with a 5% increased breast cancer risk in premenopausal women and 9% increase in postmenopausal women, said Dr. Anne McTiernan, a lead author of the new report and a cancer prevention researcher at the Fred Hutchinson Cancer Research Center in Seattle.

“I was most surprised by the alcohol result, that risk increases at just one drink a day, on average,” McTiernan said. “The increase with one drink a day was small … but the risk goes up from there. So that’s why AICR recommends no more than one alcohol drink a day for women to reduce risk for cancer.”

50% increase in breast cancer cases by 2030 01:31

For the new report, researchers analyzed 119 observational studies on breast cancer risk from around the world. Those studies included 12 million women total and more than 260,000 cases of breast cancer.

When analyzing associations specifically between breast cancer risk and alcohol use, “the premenopausal analysis included 10 large cohort studies in which over 4,000 women developed breast cancer,” McTiernan said. “The postmenopausal analysis included 22 large cohort studies in which over 35,000 women developed breast cancer.”

There are a number of possible explanations for the link between alcohol consumption and breast cancer risk, said Chin-Yo Lin, a researcher at the University of Houston’s Center for Nuclear Receptors and Cell Signaling, who was not involved in the new report.

For instance, “in exposed tissues, alcohol is converted into acetaldehyde, a chemical that can cause mutations in DNA, which can potentially lead to cancer,” Lin said.

“Alcohol consumption is also associated with elevated levels of the female sex hormone estrogen. Excessive cumulative exposure to estrogen is a major risk factor in breast cancer,” he said. “A number of studies have shown that alcohol can enhance the actions of estrogen in breast cancer cells.”

The study involved examining how alcohol affects estrogen receptor-positive breast cancer cells. In other words, these are the cancer cells that bind estrogen, which helps them grow.

Lin and his colleagues found that since alcohol promotes the expression of BRAF, this might allow the cells to grow even faster in the presence of estrogen.

The new report also includes analyses of previous studies on associations between breast cancer risk and overall diet, nutrition, physical activity and weight.

Reducing risk of breast cancer 01:01

The researchers found strong evidence suggesting that being physically active in general, from brisk walking to more vigorous activity, decreases the risk of postmenopausal breast cancer; undertaking vigorous physical activity, such as running or cycling, decreases the risk of premenopausal breast cancer.

Additionally, the researchers found that breastfeeding decreases the risk of breast cancer, and greater weight gain in adulthood increases the risk of postmenopausal breast cancer.

The researchers also found that being overweight or obese at a younger age, between 18 and 30, may decrease the risk of pre- and postmenopausal breast cancer.

“It has been seen in a lot of studies, especially for hormonally driven breast cancers, but what’s confusing is that when women are obese after menopause, they do have a higher risk,” Ligibel said.

Red meat increases breast cancer risk 01:19

And being overweight or obese throughout adulthood may increase the risk of postmenopausal breast cancer, the researchers found in the new report.

“It’s important to put this report into context,” Ligibel said. “Eating a diet that’s high in fruit and vegetables that keeps your weight in a good range, exercising regularly, limiting alcohol, those are all things that we know are good for general health. This report really strengthens that those may also be an important part of limiting your risk of breast cancer.”

On the other hand, Dr. Kathryn Ruddy, a breast medical oncologist at the Mayo Clinic College of Medicine in Rochester, Minnesota, questioned whether eating or avoiding specific foods can help prevent breast cancer.

Join the conversation

See the latest news and share your comments with CNN Health on Facebook and Twitter.

“As the report describes, it is very clear that vigorous exercise protects against the development of breast cancer, and alcohol increases the risk of breast cancer, but the data are much more limited regarding the impact of any particular food on risk,” Ruddy said.

Some studies focusing on the relationship between a certain food choice and breast cancer risk have produced contradictory results, she added.

All in all, “there are things that women can do to reduce their risk for breast cancer, and it’s never too late to start,” said McTiernan, one of the new report’s lead authors. She recommended:

Ruddy also recommends exercising and minimizing alcohol intake.

“Hopefully, there will be additional studies forthcoming to further clarify optimal strategies for prevention,” she said.

Read this article:
A drink a day tied to higher breast cancer risk, report says …

Posted in Breast Cancer | Comments Off on A drink a day tied to higher breast cancer risk, report says …

Drinking and breast cancer: Risk increases with even one …

Posted: at 4:52 pm

Drinking even a small amount of wine, beer or hard liquor every day raises the risk of breast cancer, a new study finds.

Over the years, women have gotten conflicting advice about drinking alcoholic beverages and breast cancer risk and it can be confusing, lead author Dr. Anne McTiernan told CBS News.

“There are a lot of different studies that often come up with different answers. People always say, ‘This week I’m supposed to only drink one drink, last week it was two,'” said McTiernan, a cancer prevention expert at the Fred Hutchinson Cancer Research Center, in Seattle.

Play Video

A new study suggests a Mediterranean diet rich in extra-virgin olive oil and plant-based foods can cut women’s breast cancer risk by almost 70-pe…

To get a better understanding of the relationship between alcohol and breast cancer risk, McTiernan and colleagues performed a meta-analysis they evaluated data from 10 previous studies involving pre-menopausal women and 22 studies involving post-menopausal women. They divvied up the data into those age groups because, McTiernan said, “Breast cancer is very different in the two groups.” None of the studies included information on women who had a genetic risk for breast cancer.

Their analysis found strong evidence that drinking the equivalent of a small glass of wine or beer a day less than one standard serving increases the risk of pre-menopausal breast cancer by 5 percent. In post-menopausal women, breast cancer risk increased 9 percent with a small daily serving of alcohol.

The “small drink” was about 10 grams of alcohol, less than the amount in a standard drink, which is 14 grams (0.6 ounces) of alcohol, said McTiernan.

According to the U.S. Centers for Disease Control and Prevention, 0.6 ounces of alcohol is about the amount found in:

It didn’t seem to matter which type of alcoholic beverage women imbibed.

“We tried looking separately at beer, wine and spirits, but none jumped out as being more or less problematic. They all showed the same trends,” McTiernan said.

Play Video

New data on breast cancer was presented in a report released Monday by four major cancer groups in the U.S., including the American Cancer Societ…

One drawback of the study was that drinking habits were all self-reported by the participants.

The findings may leave some women wondering if they should avoid alcohol entirely, but McTiernan said, “We’re not telling everybody to abstain. We’re not saying anything other than small amounts do increase the risk for breast cancer.”

McTiernan does recommend women who choose to drink alcohol consume no more than one drink on average once a day, in line with the federal government’s dietary guidelines.

These findings are part of a larger report that looked at how diet, exercise and various other lifestyle factors affect the risk of developing breast cancer. In all, they analyzed 119 studies, including data on 12 million women and 260,000 cases of breast cancer, for the new report by the American Institute for Cancer Research and the World Cancer Research Fund.

Other highlights of the report include:

“Even walking and gardening in the post-menopausal women was linked to a lower risk,” said McTiernan, who noted that women should be getting at least 150 minutes of physical activity per week.

Breast cancer is the most common form of cancer in U.S. women (aside from skins cancers). More than 252,000 new cases are expected to occur this year.

American Institute for Cancer Research (AICR) stressed that while women can’t control all of the factors linked to breast cancer risk, they can take steps to reduce their risk.

“Wherever you are with physical activity, try to nudge it up a bit, either a little longer or a little harder. Make simple food shifts to boost protection substitute veggies like carrots, bell peppers or green salad for chips and crackers and if you drink alcohol, stick to a single drink or less,” Alice Bender, AICR’s Head of Nutrition Programs, said in a press release

Women can’t start making healthy choices soon enough. McTiernan said younger women, teens and girls can practice healthy living habits now to help boost their odds against breast cancer in the future.

See more here:
Drinking and breast cancer: Risk increases with even one …

Posted in Breast Cancer | Comments Off on Drinking and breast cancer: Risk increases with even one …

Inflammatory Breast Cancer (IBC) – National Breast Cancer …

Posted: at 4:52 pm

After performing a self-breast exam, Bonnie Brooks discovered a lump and immediately scheduled an appointment with her doctor. On September 11, 2008, she was diagnosed with Stage 3 metastatic breast cancer. With a difficult treatment regiment ahead, including chemotherapy, she realized that she could not face breast cancer alone.

Watch Bonnie’s inspirational story and learn more about how she overcame breast cancer.

After performing a self-breast exam, Bonnie Brooks discovered a lump and immediately scheduled an appointment with her doctor. On September 11, 2008, she was diagnosed with Stage 3 metastatic breast cancer. With a difficult treatment regiment ahead, including chemotherapy, she realized that she could not face breast cancer alone.

Watch Bonnie’s inspirational story and learn more about how she overcame breast cancer.

Visit link:
Inflammatory Breast Cancer (IBC) – National Breast Cancer …

Posted in Breast Cancer | Comments Off on Inflammatory Breast Cancer (IBC) – National Breast Cancer …

Study: Daily alcohol use raises breast cancer risk | Living | The … – Fort Wayne Journal Gazette

Posted: at 4:52 pm

Just one glass of wine or other alcoholic drink a day significantly raises the risk of breast cancer, while vigorous exercise such as running and bicycling reduces it, according to an expansive review of research on the effects of diet, nutrition and physical activity on the disease.

The report, which was issued Tuesday, concluded that drinking the equivalent of one small glass of wine, beer or other alcohol a day about 10 grams of alcohol is linked to an increased cancer risk of 5 percent for pre-menopausal women and 9 percent for post-menopausal women. A standard drink has 14 grams of alcohol.

This suggests there is no level of alcohol use that is completely safe in terms of breast cancer, said Anne McTiernan, a cancer-prevention researcher at Fred Hutchinson Cancer Research Center in Seattle and one of the report’s lead authors. If a woman is drinking, it would be better if she kept it to a lower amount.

The review, by the American Institute for Cancer Research (AICR) and the World Cancer Research Fund, evaluated research in 119 studies encompassing data on 12 million women from around the world. It is the first such review since 2010, the groups said.

For the first time, researchers concluded evidence is strong that vigorous exercise reduces breast-cancer risk.

Pre-menopausal women who were the most active had a 17 percent lower risk of developing malignancies compared to the least active women, while post-menopausal women had a 10 percent decreased risk.

The researchers noted that many things influence cancer risk and that women can’t control factors such as a family history of cancer.

But, McTiernan said, having a physically active lifestyle, maintaining a healthy weight throughout life and limiting alcohol these are all steps women can take to lower their risk.

At the same time, she said, a healthy lifestyle is not a guarantee.

About 252,000 women in the United States are expected to be diagnosed with breast cancer this year. AICR estimates that 1 in 3 cases could be prevented if women did not drink alcohol, were physically active and maintained a healthy weight.

See the article here:
Study: Daily alcohol use raises breast cancer risk | Living | The … – Fort Wayne Journal Gazette

Posted in Breast Cancer | Comments Off on Study: Daily alcohol use raises breast cancer risk | Living | The … – Fort Wayne Journal Gazette

Despite suspended license, Kirkland naturopath may have continued practicing – Seattle Times

Posted: at 4:52 pm

Kirkland naturopath Lucinda Messers license has been suspended by the state Board of Naturopathy for a variety of violations, but she may have still been treating cancer patients in violation of the suspension, The Seattle Times has learned.

Brian Hirsh was ready to try anything to prolong his life or perhaps even cure him of stage 4 colon cancer.

In October 2012, he started treatment with naturopath Lucinda Messer at her retreat, the Goddess Sanctuary, in Kirkland.

But Messer misled him and lied, state Department of Health records reveal. She didnt consult an oncologist. She also didnt explain the risks of unproven treatments before giving them to Hirsh.

Does your naturopath have an active license, or has she/he faced discipline? Heres where you can find out:

Washington Department of Health

And when Hirsh died weeks later, Department of Health documents show Messer forged his medical records to protect herself from any repercussions.

Hirschs wife, Lauren Hirsh, filed a medical malpractice lawsuit last year in King County.

Dr. Messer gave us false hope and we paid thousands of dollars for her treatments, which we were led to believe could treat and possible cure (Mr. Hirshs) cancer, Lauren Hirshs suit alleges.

In January 2016, the Board of Naturopathy also suspended Messers license to practice for five years, citing a host of violations, including treatment with unproven therapies, falsifying medical records, failing to obtain informed consent, advertising that she could treat cancer and prescribing drugs beyond her expertise, thereby misleading cancer patients. The board does not cite specific cases, but Lauren Hirshs lawsuit alleges they involve her late husband and another patient.

When a Department of Health investigator posed as a pancreatic cancer patient during a telephone consultation in 2013, state records show Messer said, We cant say we treat cancer, but thats silly because we do. I have extensive training in integrative oncology and treat cancer patients all the time.

Despite her license suspension, the 1994 Bastyr University graduate may have still been treating cancer patients, in violation of the suspension order.

Messer is the registered agent of Vitality Vitamin, a company that records show was located in a Kirkland house where supplements and naturopath consultations were being offered. Messer promised on Vitality Vitamins website to investigate a persons illness and evaluate blood tests for cancer patients.

She also invited people to the grand opening of the company on Sept. 1, Department of Health records show. A man who answered the door of the house last week said hes lived there for six months.

The Department of Health has been investigating Messers actions with the vitamin company and three other complaints against her, including that she ordered lab tests and gave a fake prescription while suspended, according to state documents obtained through a public-records request.

Naturopathy, as defined by Washington law, is the practice of the art and science of diagnosis, prevention and treatment of disorders of the body by stimulation or support or both of the natural processes of the human body. It may include manual manipulation, the prescription, administration, dispensing, and use, except for the treatment of malignancies or neoplastic disease, of nutrition and food science and physical modalities, homeopathy and certain medicines of mineral, animal and botanical origin, hygiene and immunization and common diagnostic procedures.

Source: Revised Code of Washington

Messer, in an email to The Seattle Times, insists she has done nothing wrong. She declined to be interviewed by the newspaper.

I have helped hundreds of patients heal from several maladies including cancer, she wrote in the email. Washington is one of the most difficult states to live in if you would like to use alternative cancer therapies.

Blake Maresh, executive director of the Board of Naturopathy, said Messers actions all combined make an egregious situation. Its a serious violation of scope of practice to treat cancer. Theres nothing ambiguous in the law about that.

Messer also said she had surrendered her license in January, but thats not true, according to the Department of Health.

Asked what actions the Board of Naturopathy could take, Maresh said it could increase the length of Messers license suspension, ask her to surrender her license or revoke it, if the board determines shes recently treated patients.

But revocations are rare.

Based on an analysis of license data, The Times found the state has revoked the licenses of only two naturopaths in the past 12 years, one for sexual contact with patients and another for giving his own expired prescription to a patient.

For a license to be revoked, there has to be without a reasonable doubt that they cant be rehabilitated, said Katherine Slater-Einert, a case manager for the Board of Naturopathy.

In the lawsuit, Messer is accused of shortening the life of Hirsh by telling him chemotherapy treatments were unnecessary. Had he received those treatments from an oncologist, the lawsuit states, he would have extended his life by a year or two, based on an oncologists estimate.

A court document provided by Messer shows the lawsuit has been settled but a judge hasnt signed off.

Shortly after arriving at the spa, also known as Pacific Health Restoration Center, Hirsh received a regime of laetrile, which contains cyanide and is banned by the Food and Drug Administration. Treatments also included a Rife machine, a device that transmits radio waves that purportedly treat cancer. There is no scientific evidence that shows it cures cancer, according to the National Institutes of Health.

Messer forged Hirshs signature on an informed-consent form and was misleading in maintaining she had consulted with his oncologist, according to a Department of Health statement of charges.

The Times, in a three-part series in 2007, identified the Rife machine as one of many illegal devices used to con patients into believing it would cure a myriad illnesses.

Neither Lauren Hirsh nor her attorney returned calls for comment.

Messer also treated Willow Lovage after she was diagnosed with rectal cancer.

In a lawsuit, Lovage said she stopped chemotherapy and radiation because of vomiting and diarrhea, and turned to Messer for help in July 2012.

Among the treatments Messer allegedly prescribed were laetrile and three castor oil enemas per day for three months. Messer then hired Lovage to work off her bill by cleaning the residential spa, serving soup to patients and presenting workshops on the enemas, according to her lawsuit.

Lovage suffered cyanogenic poisoning, according to the lawsuit. The Goddess Sanctuary is no longer in business.

All of the patients that Lovage was hired to help care for are now dead, the lawsuit alleged.

Lovage settled the lawsuit in 2016. Lovage and her attorney also didnt return calls.

This isnt the first time Messer has been sued following the death of a patient.

In 2001, Megan Wilson, 16, who had chronic asthma, was having trouble breathing, according to a 2006 story in The Seattle Weekly.

While waiting to be seen by Messer in her office, Wilson was treated by an acupuncturist. Then Messer gave Wilson a vitamin B-12 shot and herbal remedy without evaluating her. Messer claims she told the family to go to the hospital if the asthma worsened, but Wilsons mother contends Messer told her to return the next day if her daughters condition didnt improve, the newspaper reported.

Shortly after going home, Wilson couldnt breath and lost consciousness as her father drove her to the Lakeshore Clinic. She died in the parking lot of an asthmatic attack. After the Wilson family filed a lawsuit alleging negligence by Messer, Messer told The Seattle Weekly she settled it for $250,000 to $300,000.

Messer denied any wrongdoing and was cleared by the Board of Naturopathy.

Visit link:
Despite suspended license, Kirkland naturopath may have continued practicing – Seattle Times

Posted in Cancer Cures | Comments Off on Despite suspended license, Kirkland naturopath may have continued practicing – Seattle Times

Successful US patent strategy – Oncology Ventures Irofulven Claims … – GlobeNewswire (press release)

Posted: at 4:52 pm

May 29, 2017 10:30 ET | Source: Medical Prognosis Institute Successful US patent strategy OVs Irofulven Claims Accepted.pdf

Hoersholm; May 29th, 2017 – Medical Prognosis Institute (MPI:ST) today announced that Oncology Venture a spinout from MPI using MPI’s DRP technology for drug development was informed by the US Patent Office that it will allow the claims in a patent application for a response predictor (DRP(TM)) for Oncology Ventures anticancer drug Irofulven. A patent will be issued by the US Patent Office in the near future. The Orange Book allows listing of biomarker patents that are required for the screening of patients for treatment with a specific drug. After that, a generic drug cannot be filed to replace Irofulven for as long as the biomarker patent is valid.

“The granting of the patent on Irofulven in combination with its DRP is supporting MPI’s patent strategy as Irofulven is now protected by for 20 years by the listing in the FDA Orange Book,” Peter Buhl Jensen, M.D., CEO of MPI commented.

Oncology Venture is developing the phase 2 drug candidate Irofulven, together with a companion diagnostic technology (Irofulven DRP(TM)) to identify patients highly likely to respond to Irofulven therapy. The Irofulven DRP(TM) companion diagnostic is derived from the Drug Response Predictor (DRP(TM)) Platform of Medical Prognosis Institute (MPI) and out-licensed to OV. Previous substantial clinical investigations in 38 clinical trials (19 published) of Irofulven by US biotech company MGI Pharma and pharmaceutical company Eisai led to objective responses in subsets of patients, including for a range of hard to treat cancers; such as prostate, ovarian, liver and pancreatic cancer. Utilizing the DRP Platform, genetic signatures have been identified associated with response to Irofulven.

About The Orange Book The Orange Book identifiesdrugproducts approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act. The main criterion for the inclusion of any product is that the product is the subject of an application with an effective approval that has not been withdrawn for safety orefficacyreasons. Inclusion of products on the List is independent of any current regulatory action through administrative or judicial means against a drug product. The Orange Book lists patents that are purported to protect each drug. Patent listings and use codes are provided by the drug application owner, and the FDA is obliged to list them. In order for a generic drug manufacturer to win approval of a drug under the Hatch-Waxman Act, the generic manufacturer must certify that they will not launch their generic until after the expiration of the Orange Book-listed patent, or that the patent is invalid, unenforceable, or that the generic product will not infringe the listed patent.

About Irofulven Irofulven (6-hydroxymethylacylfulvene) is a semi-synthetic derivative of illudin S, a natural toxin isolated from the Jack O’lantern mushroom (Omphalotus illudens). A pro-drug, Irofulven requires catalysis by prostaglandin reductase 1 to become active. Created at the University of California, San Diego (UCSD), Irofulven was exclusively licensed to US biotech company MGI Pharma, which was acquired by Eisai in 2007. After being returned to UCSD in 2009, Lantern Pharma licensed Irofulven in 2015, and subsequently sub-licensed Irofulven to Oncology Venture. Irofulven is more active in vitro against tumour cells of epithelial origin and is more resistant than other alkylating agents to deactivation by p53 loss and MDR1. Irofulven exhibits impressive anti-cancer results in xenograft models in vivo, shows synergy with topoisomerase I inhibitors, and has demonstrated activity against cell lines that are resistant to other therapies. Irofulven has significant scope for combination with other therapies, including standard chemotherapeutic regimes.

About MPI’s multiple biomarker called Drug Response Predictor – DRP(TM) MPI’s DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anti-cancer drug. In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP(TM) is a Big Data tool based on messenger RNA. The DRP(TM) platform can be used in all cancer types, and has been patented for more than 70 anti-cancer drugs in the US.

About MPI Medical Prognosis Institute a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI’s exceptional opportunity to personalize cancer treatment – begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI’s DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,000 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.

* Adjuvant systemic therapy in early breast cancer: impact of guideline changes and clinicopathological factors associated with nonadherence at a nation-wide level. A. M. F. Verschoor et al. Published online: 12 August 2016 Springer Science+Business Media New York 2016

For further information, please contact: CEO, Peter Buhl Jensen, Adjunct Professor, MD, Ph.D. Ulla Hald Buhl, IR & Communication E-mail: E-mail: Telephone: +45 21 60 89 22 Telephone +45 21 70 10 49

This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on May 29th, 2017.

Certified Advisor: Sedermera Fondkommission, Norra Vallgatan 64, 211 22, Malm, Sweden

Related Articles

See the rest here:
Successful US patent strategy – Oncology Ventures Irofulven Claims … – GlobeNewswire (press release)

Posted in Oncology | Comments Off on Successful US patent strategy – Oncology Ventures Irofulven Claims … – GlobeNewswire (press release)

How AstraZeneca’s Oncology Segment Performed in 1Q17 – Market … – Market Realist

Posted: at 4:52 pm

Exploring AstraZenecas Valuation following Its 1Q17 Earnings PART 5 OF 8

AstraZenecas (AZN) Oncology segment has consistently reported revenue growth over the last few years, and its oneof the companys key areas of focus.

The segment reported a rise of 21% in its 1Q17 revenue at a constant exchange rate. Its reported revenue was $885 million in 1Q17, driven by revenue growth in Tagrisso and Lynparza, along with its legacy products such as Faslodex and Zoladex. Its revenue rise was partially offset by the weak performances of Iressa, Casodex, and Arimidex.

Faslodex is an oncology drug used for the treatment of post-menopausal women with advanced or metastatic breast cancer. The drug reported a revenue rise of 13% at constant exchange rates to $214 million in 1Q17. Its growth was driven by strong performances in US and emerging markets, partially offset by lower sales in European markets.

Zoladex is an oncology drug used for the treatment of prostate cancer in men and breast cancer or endometriosis in women. Zoladex reported a revenue rise of 5% at constant exchange rates to $185 million in 1Q17. The rise was driven by the drugs strong performance in emerging markets, substantially offset by lower sales in the US and European markets.

Lynparza, a drug for treating ovarian cancer, reported a 32% revenue rise at constant exchange rates to $57 million in 1Q17. The growth was driven by the drugs strong performance in European markets, partially offset by its lower sales in US markets.

Tagrisso is one of the new drugs in AstraZenecas Oncology segment. The drug reported a rise of over 100% in revenue to $171 million in 1Q17.

To divest risk, investors can consider ETFs such as the iShares S&P Global 100 ETF (IOO), which holds ~0.7% of its total assets in AstraZeneca. IOO also holds 3.1% of its total assets in Johnson & Johnson(JNJ), 2.0% in Novartis (NVS), and 1.8% in Merck & Co. (MRK).

Read more here:
How AstraZeneca’s Oncology Segment Performed in 1Q17 – Market … – Market Realist

Posted in Oncology | Comments Off on How AstraZeneca’s Oncology Segment Performed in 1Q17 – Market … – Market Realist

Page 11234..1020..»